Clovis Oncology (CLVS) Reports FDA Doesn't Plan to Hold Advisory Committee Meeting on Rucaparib NDA

September 8, 2016 9:28 AM EDT Send to a Friend
Clovis Oncology (NASDAQ: CLVS) today disclosed in an SEC filing:The Food and Drug Administration (“FDA”) has notified ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login